Rheumatoid Arthritis UK: Early Symptoms & Why Timing Matters

A clinically reviewed UK conditions guide to rheumatoid arthritis — autoimmunity, symptoms, how it differs from osteoarthritis, diagnosis criteria, DMARD treatment, and why early treatment matters.

What Is Rheumatoid Arthritis?

Rheumatoid arthritis is a chronic, systemic autoimmune inflammatory condition. The immune system mistakenly attacks the synovium — the thin membrane lining synovial joints — triggering a persistent inflammatory cascade that causes the synovial membrane to thicken (pannus formation), erodes articular cartilage and underlying bone, stretches and damages ligaments and tendons, and over time causes irreversible joint deformity.

It is important to understand that RA is not simply a joint disease. The same inflammatory process causes systemic effects: fatigue, anaemia, cardiovascular risk, lung involvement, dry eyes and mouth (secondary Sjögren’s), and peripheral neuropathy. Life expectancy is reduced in RA primarily through accelerated cardiovascular disease — a risk that is significantly reduced by effective disease control.

How Common Is Rheumatoid Arthritis?

RA has a prevalence of approximately 0.5–1% of the UK adult population. It affects women approximately three times more commonly than men, though this ratio narrows with age. Peak onset is between 40 and 70 years, but RA can occur at any age including in children (juvenile idiopathic arthritis). Incidence in the UK appears to have been relatively stable over recent decades.

Causes: Autoimmunity and Genetics

RA results from a combination of genetic susceptibility and environmental triggers that together lead to a loss of immunological self-tolerance and autoimmune attack on joint tissue.

• Genetic factors — the HLA-DRB1 gene (which encodes MHC class II molecules involved in immune recognition) is the strongest genetic risk factor; first-degree relatives have approximately 3× increased risk; concordance in identical twins is around 15–30%, confirming that genes are necessary but not sufficient
• Autoantibodies — rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies are present in the majority of RA patients and can precede clinical disease by years; their presence predicts more erosive disease
• Smoking — the strongest known environmental risk factor for seropositive RA; doubles the risk; interacts with genetic susceptibility (particularly HLA-DRB1); relevant to disease severity as well as onset
• Gut microbiome — emerging evidence implicates specific periodontal bacteria (Porphyromonas gingivalis) and gut dysbiosis in the generation of citrullinated proteins that trigger anti-CCP antibody production
• Hormonal factors — pregnancy often suppresses RA; the post-partum period is associated with new-onset and flares; oestrogen’s role is complex

Symptoms

• Symmetrical joint pain and swelling — the hallmark; both sides of the body involved; the small joints of the hands (MCPs and PIPs), wrists, and feet most commonly first; proximal interphalangeal joints (PIPs) swollen in early RA produce the classic “sausage finger” appearance
• Prolonged morning stiffness — stiffness lasting more than 30–60 minutes after waking is characteristic of inflammatory arthritis; this distinguishes RA from osteoarthritis (brief morning stiffness <30 minutes)
• Fatigue — often profound and disproportionate to joint symptoms; driven by systemic inflammation; one of the most impactful symptoms on quality of life
• Systemic features — low-grade fever, weight loss, malaise; particularly at disease onset
• Joint deformity — in established or inadequately treated disease: ulnar deviation of fingers, boutonniere and swan-neck deformities, subluxation
• Extra-articular features — rheumatoid nodules (firm subcutaneous nodules); dry eyes and mouth (secondary Sjögren’s); lung involvement (interstitial lung disease, pleural effusion); vasculitis (rare)

How RA Differs from Osteoarthritis

Diagnosis

Diagnosis is made using the 2010 ACR/EULAR classification criteria, incorporating joint involvement pattern, serology (RF and anti-CCP), acute phase reactants (CRP and ESR), and duration of symptoms. Key investigations include:

• Rheumatoid factor (RF) — positive in ~70% of RA patients; not specific to RA; negative RF (“seronegative RA”) does not exclude the diagnosis
• Anti-CCP antibodies — more specific than RF; highly predictive of erosive disease; positive anti-CCP in the context of inflammatory arthritis strongly supports RA
• CRP and ESR — markers of systemic inflammation; elevated in most active RA
• FBC — anaemia of chronic disease; thrombocytosis during active disease
• X-ray of hands and feet — periarticular osteopenia and erosions confirm diagnosis and provide baseline; ultrasound detects synovitis and erosions earlier

NICE guidance (NG100) recommends that patients with suspected RA should be referred urgently to rheumatology — BSR/BHPR guidance supports a 3-week target for active synovitis — and should be started on DMARDs within 3 months of confirmed diagnosis.

Disease Course and Prognosis

RA follows a variable course. Without adequate treatment, most patients experience progressive joint damage, functional decline, and significant disability. With modern DMARD therapy, many patients achieve remission or low disease activity — a treatment goal that was rarely achievable two decades ago.

Poor prognostic factors include: positive anti-CCP, high disease activity at presentation, early erosions on imaging, multiple joint involvement, and poor functional status at diagnosis. These factors support earlier and more aggressive treatment escalation.

Treatment Overview

DMARDs: The Cornerstone of Treatment

Disease-modifying antirheumatic drugs (DMARDs) fundamentally change the course of RA — reducing inflammation, preventing joint erosion, preserving function, and reducing cardiovascular risk. Methotrexate is the standard first-line DMARD, given weekly (oral or subcutaneous) with folic acid supplementation to reduce side effects. It requires regular blood monitoring (LFTs, FBC) throughout treatment.

For patients who do not respond adequately to conventional DMARDs, biologic agents targeting specific cytokines (primarily TNF-α) or immune cells are highly effective. These require NICE approval criteria, specialist initiation, and regular clinical review.

Treat-to-target is the modern paradigm in RA management: aiming for clinical remission or low disease activity, adjusting treatment until the target is achieved, and maintaining it. This approach has transformed outcomes in RA over the past 20 years.

When to Seek Help — Urgency Matters

• Symmetrical swelling of small joints — particularly both hands and wrists simultaneously
• Morning stiffness lasting more than 30 minutes
• Persistent joint pain and swelling not explained by injury
• Significant unexplained fatigue alongside joint symptoms
• Symptoms in multiple joints simultaneously